therapeutics
FREE subscriptions for doctors and students... click here
You have 3 more open access pages.
Examples of evidence include:
Last reviewed 03/2020
Links:
- diabetes control and complications trial
- CALM study
- UK Prospective Diabetes Study
- orlistat in obese type II diabetics
- HOPE study
- MRC / BHF Heart Protection Study
- Proactive (PROspective pioglitAzone Clinical Trial In macroVascular Events) study
- EMPA - REG trial - empagliflozin in type 2 diabetes patients with high cardiovascular risk (EMPAREG)
- CANVAS Program - Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial
- SUSTAIN-6 - subcutaneous semaglutide and cardiovascular outcomes in type 2 Diabetes
- DECLARE - TIMI 58 - dapagliflozin and cardiovascular outcomes in type 2 diabetes
- CREDENCE - canagliflozin and renal outcomes in type 2 diabetes (diabetic) and nephropathy
- DAPA HF
- Diabetes Remission Clinical Trial (DiRECT) using diet in diabetes